Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy - A randomized comparative dose-ranging study

被引:12
作者
Bruhat, M
Rudolf, K
Vaheri, R
Kainulainen, P
Timonen, U [1 ]
Viitanen, A
机构
[1] Policlin Hotel Dieu, Clermont Ferrand, France
[2] FCH Fertil Ctr Hamburg, Hamburg, Germany
[3] Orion Pharma, FIN-02101 Espoo, Finland
关键词
estrogen-progestogen regimens; hormone replacement therapy; bleeding;
D O I
10.1016/S0378-5122(01)00245-6
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: We compared two different continuous combined hormone replacement therapy (HRT) regimens of estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) with a combination of micronized estradiol (E-2) and norethisterone acetate (NETA) to determine bleeding pattern, control of climacteric symptoms, lipid profile, endometrial and general safety in a 1-year multicenter study. Methods: 440 postmenopausal women were randomized to three treatment groups to receive: I mg E2V + 2.5 mg MPA; I mg E2V + 5 mg MPA,. or 2 mg of E-2 + 1 mg NETA. After the first 6 months, the E2V dose was increased to 2 mg in both E2V/MPA groups. Information on bleeding was recorded on diaries by the women and intensity of climacteric symptoms was assessed using VAS scales. Physical and laboratory examinations, endometrial biopsy and vaginal ultrasonography were performed at baseline and follow-up visits. Results: Significantly fewer bleeding days were experienced in the first 3 months by women taking E2V/MPA compared with women. taking E-2/NETA. When the dose of E2V was increased in the E2V/MPA groups, an increase in maximum bleeding intensity was observed in the group receiving 2.5 mg of MPA, but not in the group taking 5 mg of MPA. All dose combinations effectively relieved climacteric symptoms and beneficial effects on the lipid profile were seen after 6 months in all groups. Tolerability and endometrial safety were good and no cases of hyperplasia were observed. More women discontinued treatment prematurely in the E-2/NETA group compared with either of the E2V/MPA groups. The overall continuation rates ranged from 70 to 86%. Conclusions: These results confirm that lower dose combinations of continuous combined HRT are usually sufficient to control symptoms or avoid breakthrough bleeding. However, if higher E2V dose is needed for symptom control, it should be combined with the higher dose of progestin (5 mg) to avoid bleeding disturbances. Flexible treatment regimens should be available for individualized HRT. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:259 / 271
页数:13
相关论文
共 20 条
[1]   Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate [J].
Archer, DF ;
Dorin, MH ;
Heine, W ;
Nanavati, N ;
Arce, JC .
OBSTETRICS AND GYNECOLOGY, 1999, 94 (03) :323-329
[2]   Hormone replacement therapy: Effect of progestin dose and time since menopause on endometrial bleeding [J].
Archer, DF ;
Pickar, JH .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (06) :899-905
[3]   Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy [J].
Björn, I ;
Bäckström, T .
MATURITAS, 1999, 32 (02) :77-86
[4]   SUPERIOR COMPLIANCE AND EFFICACY OF CONTINUOUS COMBINED ORAL ESTROGEN-PROGESTOGEN REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN [J].
DOREN, M ;
REUTHER, G ;
MINNE, HW ;
SCHNEIDER, HPG .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (05) :1446-1451
[5]   COMPLIANCE WITH LONG-TERM ORAL HORMONAL REPLACEMENT THERAPY [J].
EIKEN, P ;
KOLTHOFF, N .
MATURITAS, 1995, 22 (02) :97-103
[6]  
Graziottin A, 1999, MATURITAS, V33, pS15
[8]   Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal none loss: A comparison of high-and low-dose estrogen-progestin regimens [J].
Heikkinen, J ;
Vaheri, R ;
Kainulainen, P ;
Timonen, U .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (11) :929-937
[9]   Optimizing continuous-combined hormone replacement therapy for postmenopausal women:: A comparison of six different treatment regimens [J].
Heikkinen, JE ;
Vaheri, RT ;
Ahomäki, SM ;
Kainulainen, PMT ;
Viitanen, AT ;
Timonen, UM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (03) :560-567
[10]   CLINICAL AND LIPID METABOLIC EFFECTS OF UNOPPOSED ESTROGEN AND 2 ESTROGEN-PROGESTOGEN REGIMENS IN POSTMENOPAUSAL WOMEN [J].
HIRVONEN, E ;
LIPASTI, A ;
MALKONEN, M ;
KARKKAINEN, J ;
NUNTILA, J ;
TIMONEN, H ;
MANNINEN, V .
MATURITAS, 1987, 9 (01) :69-79